Beyond FimH: Diversity and Relevance of Carbohydrate-Binding Fimbrial Proteins in Escherichia coli

IF 2.8 4区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY
ChemBioChem Pub Date : 2025-07-30 DOI:10.1002/cbic.202500433
Oliwier R. Dulawa, Shane M. Coyle, Fiona Walsh, Trinidad Velasco-Torrijos
{"title":"Beyond FimH: Diversity and Relevance of Carbohydrate-Binding Fimbrial Proteins in Escherichia coli","authors":"Oliwier R. Dulawa,&nbsp;Shane M. Coyle,&nbsp;Fiona Walsh,&nbsp;Trinidad Velasco-Torrijos","doi":"10.1002/cbic.202500433","DOIUrl":null,"url":null,"abstract":"<p><i>Escherichia coli</i> (<i>E. coli</i>) is responsible for multiple diseases in humans and animals. Many of them are treated with antibiotics; however, the need for new therapies has led to research in alternative treatments. One such approach involves preventing the adherence of <i>E. coli</i> to host cells by inhibiting their adhesins. Adherence is a crucial step of pathogenesis, and bacterial lectins that recognize host glycans play major roles in host cell adhesion. In fact, lectins are the most common bacterial adhesins. The various pathogenic and nonpathogenic <i>E. coli</i> strains express a multitude of lectins, many of which are found on <i>E. coli</i> fimbriae. Current research on lectin inhibition using glycomimetics has produced many mannose-based inhibitors of the uropathogenic <i>E. coli</i> fimbrial lectin FimH. However, only a limited number of synthetic inhibitors are reported for other lectins. In this review, many other cell surface adhesins of <i>E. coli</i> are discussed, focusing on fimbrial lectins. The types of <i>E. coli</i> strains they are found in, their carbohydrate targets, and their binding sites are also discussed. This review aims to highlight the many lectins that can become therapeutic targets to treat <i>E. coli</i> infections in addition to FimH.</p>","PeriodicalId":140,"journal":{"name":"ChemBioChem","volume":"26 17","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12442223/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemBioChem","FirstCategoryId":"99","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.202500433","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Escherichia coli (E. coli) is responsible for multiple diseases in humans and animals. Many of them are treated with antibiotics; however, the need for new therapies has led to research in alternative treatments. One such approach involves preventing the adherence of E. coli to host cells by inhibiting their adhesins. Adherence is a crucial step of pathogenesis, and bacterial lectins that recognize host glycans play major roles in host cell adhesion. In fact, lectins are the most common bacterial adhesins. The various pathogenic and nonpathogenic E. coli strains express a multitude of lectins, many of which are found on E. coli fimbriae. Current research on lectin inhibition using glycomimetics has produced many mannose-based inhibitors of the uropathogenic E. coli fimbrial lectin FimH. However, only a limited number of synthetic inhibitors are reported for other lectins. In this review, many other cell surface adhesins of E. coli are discussed, focusing on fimbrial lectins. The types of E. coli strains they are found in, their carbohydrate targets, and their binding sites are also discussed. This review aims to highlight the many lectins that can become therapeutic targets to treat E. coli infections in addition to FimH.

Abstract Image

Abstract Image

Abstract Image

超越FimH:大肠杆菌中碳水化合物结合边缘蛋白的多样性和相关性。
大肠杆菌是人类和动物多种疾病的罪魁祸首。其中许多人接受了抗生素治疗;然而,对新疗法的需求导致了对替代疗法的研究。其中一种方法是通过抑制大肠杆菌的粘附素来防止其粘附宿主细胞。粘附是其发病机制的关键步骤,而识别宿主聚糖的细菌凝集素在宿主细胞粘附中起着重要作用。事实上,凝集素是最常见的细菌黏附素。各种致病性和非致病性大肠杆菌菌株表达大量凝集素,其中许多凝集素存在于大肠杆菌菌毛上。目前利用糖仿制品抑制凝集素的研究已经产生了许多以甘露糖为基础的尿致病性大肠杆菌菌毛凝集素FimH抑制剂。然而,只有有限数量的合成抑制剂被报道用于其他凝集素。本文综述了大肠杆菌的许多其他细胞表面粘附素,重点介绍了毛状凝集素。还讨论了它们存在的大肠杆菌菌株的类型、它们的碳水化合物靶点和它们的结合位点。本综述旨在强调除FimH外,许多凝集素可以成为治疗大肠杆菌感染的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ChemBioChem
ChemBioChem 生物-生化与分子生物学
CiteScore
6.10
自引率
3.10%
发文量
407
审稿时长
1 months
期刊介绍: ChemBioChem (Impact Factor 2018: 2.641) publishes important breakthroughs across all areas at the interface of chemistry and biology, including the fields of chemical biology, bioorganic chemistry, bioinorganic chemistry, synthetic biology, biocatalysis, bionanotechnology, and biomaterials. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies, and supported by the Asian Chemical Editorial Society (ACES).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信